Himax Technologies, Inc. (NASDAQ:HIMX) recorded a trading volume of 4.54 million shares, below its 90-day volume average of 6.34 million shares. The stock kicked off the session at $10.61 and later approached $10.66 with a change of 0.47%.Himax Technologies, Inc. (HIMX) Analyst Opinion
Himax Technologies, Inc. has a consensus outperform rating from 11 Wall Street analysts, and the number of shares currently sold short amount to at least 16.87% of shares outstanding. The stock spiked 5.23% last month and is up 76.49 this year. Wall Street is only getting more bullish on the stock, with 8 of analysts who cover HIMX having a buy-equivalent rating. Analysts have placed a $10.54 price target on Himax Technologies, Inc., suggesting a -1.13% decline from recent close. It’s currently trading about -10.94% below its 52-week high.Himax Technologies, Inc. Earnings Surprise
Himax Technologies, Inc. (HIMX) failed to surprise the stock market in its last reported earnings when it earned -$0 a piece versus the consensus-estimated -$0. Its revenue totaled $153.66 million down -1% from the previous quarter.Himax Technologies, Inc. (NASDAQ:HIMX) Intraday View
This stock (HIMX) is ahead of its 52-week low with 118.44%. Its last month’s stock price volatility remained 4.12% which for the week stands at 4.43%. The share price has moved forward from its 20 days moving average, trading at a distance of 6.87% and stays 4.01% away from its 50 days moving average. Over the last five days, shares have faced -1.3% losses and now is up 28.38% since hitting its 200-day moving average of $8.7. Himax Technologies, Inc. (HIMX) has made its way to a 12-month gain of 39.71%.
Turning to Novo Nordisk A/S (NYSE:NVO), its shares were trading at $50.27 a gain of $0.56, on the trading floor. The stock, after opening at $49.65, touched a high of $50.405 before paring much of its gains. So far, analysts are sticking with their bearish recommendations with the consensus call at 3. Novo Nordisk A/S has 0 buy ratings, 1 holds and 0 sells even after the stock tumbled -1.33% from its high of $50.95 to a $97.88 billion market value through last close.Novo Nordisk A/S (NVO) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 3 to 3 during a month. Analysts set a 12-month price target of $50.2 a share. The target implies a -0.14% decrease from where the shares are currently trading. Also, the current price highlights a discount of 25.12% to analysts’ high consensus price target.Novo Nordisk A/S (NYSE:NVO) Intraday Trading
The counter witnessed a trading volume of 2.64 million shares versus an average volume of 2.04 million shares during last trading session. Its last month’s stock price volatility remained 1.13% which for the week approaches 1.11%. The lowest price the stock reached in the last trading day was $49.63 and compares with the $30.89 52-week low. The stock recovered 62.74% since its low point and has performed 40.18% year-to-date.